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ActivityAbstract Background: Human leukocyte antigen HLA-DRB1 alleles encoding a common amino
acid sequence called shared epitope in the third hypervariable region of DRB1 molecule have been
identified as risk alleles for rheumatoid arthritis (RA).
Aim of the work: The aim was to study HLA-DRB1 01, 04 and 10 alleles in Egyptian RA
patients and determine their relation with anticyclic citrullinated peptide (anti-CCP) antibody level,
disease activity, clinical and radiological severity.
Patients and methods: The study involved 40 RA patients and 20 control. Simplified disease
activity index (SDAI) was calculated, clinical severity was assessed using the mechanical joint score
(MJS) and radiological severity evaluated using the simple erosion narrowing score (SENS). HLA-
DRB1 genotyping and anti-CCP antibodies were detected.
Results: The mean patients’ age was 41.6 ± 12.7 years and disease duration 8.9 ± 7.7 years. The
frequency of HLA DRB1 01, 04 and 10 in patients was 42.5%, 60% and 25% respectively. Of them
04 was significantly higher than in controls (p= 0.013) and was associated with anti-CCP positive
cases (p= 0.0008) while the absence of HLA-DRB1 alleles was significantly associated with nega-
tive anti-CCP negative RA (p= 0.0008). There were significant associations between HLA-DRB1
01 and 04 with SDAI (p= 0.0002 and p= 0.005, respectively); between HLA-DRB1 04 and 10
with SENS (p= 0.002 and p= 0.001 respectively) and between HLA-DRB1 01, 04 and 10 with
MJS (p= 0.02, p= 0.03 and p= 0.02, respectively).t. Mob.:
270 A.F. Soliman et al.Conclusion: HLA-DRB1 04 is associated with RA in Egyptian patients and is strongly associ-
ated in the production of elevated titers of anti-CCP antibodies which contribute to the develop-
ment, severity and activity of the disease.
 2016 Publishing services provided by Elsevier B.V. on behalf of Egyptian Society of Rheumatic
Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid arthritis (RA) is an autoimmune chronic inflam-
matory disease and the genetic factor may be concerned in dis-
ease initiation and in the severity of its course [1]. The human
leukocyte antigen (HLA) region, also well known as the major
histocompatibility complex (MHC), has an impact on the
genetic risk and may account for RA susceptibility [2,3] in
50–60% of cases [4]. In particular, HLA–DRB1 alleles encod-
ing a common amino acid sequence called the shared epitope
(SE) in the third hyper-variable region have been identified
as risk alleles for RA [2]. These alleles are also associated with
a more severe disease type [5,6].
Rheumatoid arthritis is characterized by the presence of
various autoantibodies [7]. Best well known are the rheuma-
toid factors (RFs), which are antibodies against the Fc part
of the immunoglobulin (IgG) molecules. They are not specific
for RA; however, the detection of RF (IgM) is used in RA
diagnosis [8]. Yet, anti-cyclic citrullinated peptide (anti-CCP)
antibodies are highly specific markers for diagnosis of RA
[9], preceding the appearance of the disease [10] and are
reported to be good predictors for the development of RA
[9]. They are also associated with a more severe disease course
[9,11]. These data suggest that these antibodies have a causa-
tive role in the pathogenesis of RA [12,13].
The shared epitope hypothesis proposes that the SE plays a
role in the presentation of ‘arthritogenic’ antigens to T lym-
phocytes [3]. Anti-CCP antibodies are directed to antigens con-
taining the non-standard amino acid citrulline [14,15], for
example, citrullinated fibrin which is found in the rheumatoid
joint [16,17]. Although citrullination or SE deimination of
arginine residues of proteins may result in the formation of
epitopes that are targets of antibodies, help from T lympho-
cytes is likely required for long-term B cell responses and anti-
body isotype switching. Accordingly, in transgenic mice for
one of the SE alleles ‘HLA–DRB1*0401’ it was demonstrated
that citrullination of arginine residues of peptides at the pep-
tide side-chain position interacting with the SE, significantly
increases peptide–MHC affinity. This leads to an increased
binding of these citrullinated peptides to MHC class II mole-
cules leading to the activation of CD4-positive T cells [18].
Since not all RA patients have anti-CCP antibodies [14], this
suggests that the presence of anti-CCP antibodies is not
obligatory for the development of arthritis or that the
pathogenic mechanisms underlying anti-CCP-positive and
anti-CCP-negative RA are different. It was reported that the
phenotype of RA patients with anti-CCP antibodies is similar
to that without with respect to clinical presentation but differs
in the disease course [19].
Since these data are showing an existing relation between
anti-CCP antibodies and SE alleles and anti-CCP is highly
specific for RA, a thorough analysis of HLA class II alleles
involved in generating autoantibodies to citrullinated antigensis important to gain a better understanding of this particular
immune response [12]. In this study, we aimed to study
HLA-DRB1 01, 04 and 10 alleles in Egyptian RA patients
and determine their relation with anti-CCP antibody level, dis-
ease activity, clinical and radiological severity.2. Patients and methods
This study included 40 RA patients selected from the Rheuma-
tology, Rehabilitation and Physical Medicine Department,
Benha University Hospitals, Benha City, Qualyobia gover-
norate, Egypt. They were diagnosed according to the 2010
EULAR/ACR criteria [20]. 20 age and sex matched healthy
volunteers were included as the control group. Patients were
enrolled in the study after taking written informed consents
from them. The study was approved by the ethics committee
of the Faculty of Medicine, Benha University.
All the patients were subjected to full history taking and
thorough clinical examination with stress on the locomotor
system. Clinical disease severity was assessed using the
mechanical joint score (MJS) [21]. A postero–anterior plain
radiographic view of both hands was obtained for the assess-
ment of radiological severity using the simple erosion narrow-
ing score (SENS) [22] derived from the Sharp/van Der Heijde
method as a simplified and easier scoring method. Disease
activity was assessed using the simplified disease activity index
(SDAI) [23].
Laboratory investigations were performed on the patients
and control including the erythrocyte sedimentation rate
(ESR), serum C-reactive protein (CRP) (CRP LATEX TEST
KIT; BIOTEC Laboratories Ltd) (positive results P6 lg/ml)
and serum rheumatoid factor (RF) by nephelometry (Turbox
RF-PAIA KIT; Orion Diagnostica) done on Turbox plus
analyzer (positive results P25 IU/ml). Serum anticyclic citrul-
linated peptide antibodies (anti-CCP3) were assessed by semi-
quantitative enzyme-linked immunosorbent assay (ELISA)
(QUANTA LiteTM CCP3 IgG ELISA kit supplied by
INOVA Diagnostics, Inc.-USA). Assessment was according
to the manufacturer’s instructions. Results P20 U/ml were
considered positive. Blood collected on EDTA containing
tubes were stored at 80 C for later HLA-DRB1 genotyping.
2.1. HLA-DRB1 genotyping
Genomic DNA was extracted from 200 ll of whole blood
using QIA amp DNA blood mini kits, catalog number
51104, supplied by Qiagen-Germany according to the manu-
facturer’s instructions. Two-hundred ll of DNA was eluted.
The extracted DNA was then stored at - 20 C until further
processing. HLA-DRB1 alleles (DRB1 01, DRB1 04, DRB1
10) were identified by conventional polymerase chain reaction
(PCR) using specific primers, common reverse primer CTC
Table 1 Demographic features and laboratory parameters of the RA patients and control as well as the
clinical characteristics, medications used disease activity and severity of the RA patients.
Parameter mean ± SD (range) or n (%) RA patients (n= 40) Control (n= 20)
Age (years) 41.6 ± 12.7 (20–66) 43.3 ± 13.9 (20–64)
Age at disease onset (years) 32.7 ± 7.03 (18–50) –
Disease duration (years) 8.9 ± 7.7 (1–30) –
Sex: female:male 36 (90): 4 (10) 17 (85): 3 (15)
Smoking 4 (10) 3 (15)
EA manifestations 4 (10) –
Disease activity
SDAI 22.96 ± 13.6 (7.5–49.3) –
mild 23 (57.5)
moderate 10 (25)
severe 7 (17.5)
Disease severity
Clinical: MJS 12.2 ± 12.1 (0–38) –
Radiological: SENS 22.8 ± 24.9 (2–76) –
Medications
Methotrexate mg/w (n= 32) 14.9 ± 7.4 –
Prednisolone mg/d (n= 15) 4.1 ± 5.6 –
Leflunomide mg/d (n= 8) 4.0 ± 7.9 –
Chloroquine mg/d (n= 21) 125 ± 133.6 –
Laboratory parameters
Anti-CCP positivity
20 (50)
0 (0)
RF positivity 29 (72.5) 0 (0)
CRP positivity 30 (75) 0 (0)
High ESR (mm/1st hr) 31 (77.5) 0 (0)
RA: rheumatoid factor, EA: extra-articular, SDAI: simplified disease activity index, MJS: mechanical joint score,
SENS: simple erosion narrowing score, anti-CCP: anti-cyclic citrullinated peptide, RF: rheumatoid factor, CRP: C-
reactive protein, ESR: erythrocyte sedimentation rate.
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CTT GTG GCA GCT TAA GTT TGA AT, forward primer
for DRB1 04 GTT TCT TGG AGC AGG TTA AAC and,
forward primer for DRB1 10 CAC AGC ACG TTT CTT
GGAGG [24]. Amplification was done using Taq PCRMaster
Mix Kit supplied by Qiagen. The PCR mix for each allele con-
tained 25 ll of Taq PCR master. Mix 2, 2.5 ll (0.5 lM) of
forward primer, 2.5 ll (0.5 lM) of reverse primer, 10 ll of
the template DNA and 10 ll of nuclease free water to reach
a final volume of 50 ll. G storm thermal cycler-UK was used
for amplification according to the following program: initial
denaturation at 94 C for 3 min., 35 cycles of denaturation at
94 C for 30 s., annealing at 53 C for 30 s. and extension at
72 C for 1 min., followed by final extension at 72 C for
10 min. then hold at 4 C. 10 ll of each amplified DNA &
1000 bp ladder (molecular weight marker) were separated on
2% agarose gel containing 0.3 lg/ml of ethidium bromide,
photographed and analyzed (agarose gel electrophoresis)
Statistical analysis: The collected data were computed and
statistically analyzed using SPSS version 17 software for win-
dows (SPSS Inc., Chicago). Suitable statistical techniques were
calculated as range, mean, standard deviation, median and fre-
quency (percentage). Chi square and Z tests were used to test
the significance for frequency and the corrected Chi square test
for frequencies <5. Student’s t test and ANOVA were used for
comparison of 2 groups and >2 groups respectively. Oddsratio (OR) with 95% confidence interval (95% CI) values were
also calculated. Pearson correlation coefficient was estimated
to correlate the DRB1 genotypes and anti-CCP antibody level.
P values <0.05 were considered significant.3. Results
Forty Egyptian RA patients with a mean age of 41.6
± 12.7 years (range: 20–66 years) and 20 control with a mean
age of 43.3 ± 13.9 years (range: 20–64 years) were included in
the study. The demographic features and laboratory parame-
ters of the RA patients and control as well as the clinical char-
acteristics of the patients are presented in Table 1.
The frequency of HLA-DRB1 01, 04 and 10 in RA patients
and control are shown in Table 2. Only the frequency of 04
allele was significantly higher in RA patients compared to
the controls.
The relation of the studied HLA-DRB1 01, 04, 10 alleles
with the different demographic and clinical parameters in RA
patients is presented in Table 3. The disease duration was sig-
nificantly (p= 0.0014) longer in HLA-DRB1 10 positive cases.
The SDAI was significantly higher in RA patients with positive
01 and 04 alleles (p= 0002 and p= 0.005, respectively). Clin-
ical disease severity (MJS) was significantly higher in patients
with positive 01, 04 and 10 alleles (p= 0.022, p= 0.03 and
Table 2 Frequency of HLA-DRB1 01, 04 and 10 in RA
patients and control.
HLA-DRB1
frequency n (%)
RA patients
(n= 40)
Control
(n= 20)
p OR (95% CI)
01 17 (42.5) 6 (30) 0.35 1.7 (0.6–5.4)
04 24 (60) 5 (25) 0.013 4.5 (1.4–14.8)
10 10 (25) 2 (10) 0.18 3 (0.6–15.3)
No alleles 10 (25) 10 (50) 0.06 0.3 (0.1–1.03)
HLA: Human leukocyte antigen, RA: rheumatoid arthritis. Bold
value is significant at p< 0.05.
272 A.F. Soliman et al.p= 0.02, respectively). However, radiological disease severity
(SENS) was significantly higher in those with a positive 04 or
10 allele (p= 0.002 and p= 0.001, respectively).
Frequency of HLA-DRB1 genotypes among anti CCP and
RF positive and negative RA patients is presented in Table 4.
A positive 04 allele was the only HLA-DRB1 significantly
associated with anti-CCP positivity (p= 0.0008). The presence
of P1 alleles was significantly associated with a positive
anti-CCP (p= 0.0008). The anti-CCP antibodies were positive
in 13 of the 29 RF sero-positive RA patients (44.8%) and in 7
of the 11 RF negative RA patients (63.6%). There was a
significant correlation of the serum anti-CCP antibodies level
with a P1 positive allele (p= 0.003), a positive 04 and 10
(p= 0.035, p= 0.005) alleles. Anti-CCP antibodies were also
significantly correlated with the disease activity (p= 0.032),
clinical (p= 0.034) and radiological severity scores
(p= 0.033) (Table 5).
4. Discussion
The HLA-DRB1 alleles encoding the SE were found to be
associated with the severity and susceptibility of RA andTable 3 Relation of the studied HLA-DRB1 01, 04 and 10 statu
rheumatoid arthritis patients.
Parameter mean
± SD
(range) or n (%)
HLADRB1 in RA patients (n= 40)
01 04
Positive
(n= 17)
Negative
(n= 23)
Positive
(n= 24)
Age 41.8 ± 14.7 41.4 ± 11.2 43.5 ± 1
Age at onset 31.6 ± 6.6 33.4 ± 7.4 33.2 ± 5
Disease duration 10.2 ± 9.4 7.9 ± 6.2 10.3 ± 8
Sex F:M 17:0 19:4 24:0
Disease activity
SDAI 31.7 ± 13.4 16.5 ± 9.8** 27.7 ± 1
mild 4 (23.5) 19 (82.6)** 10 (41.7
moderate 6 (35.3) 4 (17.4) 7 (29.2)
severe 7 (41.2) 0 (0)* 7 (29.2)
Disease severity
MJS 17.2 ± 13.4 8.5 ± 9.7* 15.5 ± 1
SENS 31.1 ± 28.1 43.1 ± 13.8 38.9 ± 2
HLA: Human leukocyte antigen, RA: rheumatoid arthritis, SDAI: simplifi
erosion narrowing score.
* Significant.
** Highly significant difference from the corresponding values at p< 0.include 0101, 0102, 0104, 0401, 0404, 0405, 0408, 0413, 0416
and 1001 alleles [25]. These alleles are subtypes of HLA-
DRB1 (01, 04 and 10). The aim of this study was to evaluate
the 01, 04 and 10 alleles in the Egyptian RA patients. Our
results reported a frequency of 30%, 25% and 10% for
HLA DRB1 01, 04 and 10 respectively in the normal subjects
of Benha City in Qualyobia governorate. Their frequency in
the normal subjects of Assuit governorate was 5%, 10% and
15% respectively [26]. In Asian populations, the frequency
was 5.7%, 4.9% and 7.4% and in the European populations
it was 25.3%, 26.5% and 1.1%, respectively. However, in both
the Asian and European populations the reported frequency
was limited to some SE alleles of HLA DRB1 04 [27]. More-
over, in a Kuwaiti normal population, the frequency was
5.7%, 22.8% and 14.3% respectively [28].
On the other hand, the frequency of HLA DRB1 01, 04 and
10 in RA patients in the present study was 42.5%, 60% and
25% respectively. Of them, HLA DRB1 04 was significantly
higher in RA patients than in controls. In accordance, it was
reported that there are differences in the strength of the associ-
ation between different SE alleles and RA. The HLA–DRB1 04
alleles represent a considerably stronger susceptibility factor
than the other SE alleles [29]. Also, Alsaeid et al., [28] reported
that only HLA-DRB1 04 was significantly higher in the RA
patients. Fathi and associates [26] reported a frequency of
45%, 35% and 0% for HLA-DRB1 01, one or two 04 and 10
in RA patients respectively. Both HLA DRB1 01 and 04 were
significantly higher and 10 was significantly lower in RA
patients than in the normal control of that study. However
HLA-DRB1 10 was more prevalent in Spanish RA patients
[30]. On the other hand, in Chinese RA patients, HLA-DRB1
01 was not associated with RA but 04 frequency was signifi-
cantly higher than in the healthy Chinese individuals [31].
Our study reported a significant association of a positive
HLA-DRB1 01 and 04 with disease activity and clinical disease
severity however, positive HLA-DRB1 04 and 10 alleles weres with the different demographic and clinical parameters in the
10
Negative
(n= 16)
Positive
(n= 10)
Negative
(n= 30)
2.4 38.7 ± 12.9 41.8 ± 15. 39.2 ± 10.9
.5 31.8 ± 8.9 34.3 ± 8.7 32.1 ± 6.4
.4 6.9 ± 6.3 14.5 ± 9.6 7.1 ± 4.1*
12:4* 9:1 27:3
3.9 15.8 ± 9.6* 30.1 ± 13.1 20.5 ± 13.2
) 13 (81.3)* 3 (30) 20 (66.7)*
3 (18.8) 4 (40) 6 (20)
0 (0)* 3 (30) 4 (13.3)
2.5 7.3 ± 9.8* 20.4 ± 14 9.5 ± 10.1*
4.6 13.6 ± 22.9* 40.8 ± 31 16.8 ± 1.4*
ed disease activity index, MJS: mechanical joint score, SENS: simple
05.
Table 4 Frequency of HLA-DRB1 genotypes among anti CCP and RF positive and negative RA patients.
HLA-DRB1 genotype
frequency n (%)
Rheumatoid arthritis patients (n= 40)
Anti-CCP RF
Positive (n= 20) Negative (n= 20) OR (95CI) Positive (n= 29) Negative (n= 11) OR (95CI)
Allele 01 11 (55) 6 (30) 2.9 13 (44.8) 4 (36.4) 1.4
04 18 (90) 6 (30)** 21 19 (65.5) 5 (45.5) 2.3
10 7 (35) 3 (15) 3.1 7 (24.1) 3 (22.3) 0.9
None 0 (0) 10 (50)** – 7 (24.1) 3 (22.3) 0.9
P1 alleles 20 (100) 10 (50)** – 22 (75.9) 8 (72.7) 1.2
 1 allele 9 (45) 6 (60) 0.5 10 (34.5) 5 (45.5) 0.5
 2 alleles 6 (30) 3 (30) 1 7 (24.1) 2 (18.2) 1.4
 3 alleles 5 (25) 1 (10) 3 5 (17.2) 1 (9.1) 2.1
RA: rheumatoid factor, anti-CCP: anti-cyclic citrullinated peptide, RF: rheumatoid factor.
** Highly significant difference from the corresponding values at p< 0.05.
Table 5 Correlation of anti-CCP level with the presence of
different HLA DRB1 genotypes alleles, with disease activity,
clinical and radiological severity score in RA patients.
R (p) Anti-CCP
DRB1 genotype
01 0.21 (0.19)
04 0.43 (0.035)
10 0.53 (0.005)
P1 allele 0.56 (0.003)
Disease activity
SDAI 0.45 (0.032)
Disease severity
Clinical: MJS 0.42 (0.034)
Radiological: SENS 0.41 (0.033)
Anti-CCP: anti-cyclic citrullinated peptide, SDAI: simplified dis-
ease activity index, MJS: mechanical joint score, SENS: simple
erosion narrowing score. Bold values are significant at p< 0.05
HLA-DRB1 alleles in rheumatoid arthritis patients 273significantly associated with radiological severity. Fathi and
associates [26] reported the significant association of HLA
DRB1 04 alleles with more activity of the disease but not 01.
They also reported significant association of HLA-DRB1 01
and 04 with the radiologically severe disease. Also, Lin and
associates [31] revealed a significant association of HLA-
DRB1 04 with clinically and radiologically severe disease in
Chinese populations. However, Kinikli and associates [32]
reported no association of HLA-DRB1 01 or 04 with the clin-
ical or radiological severity of the disease in the Turkish
population.
In a previous study, anti-CCP Abs were detected in 53% of
RA patients [25]. Our study also detected them in 50% of RA
Egyptian patients. Moreover our work like previous studies
have documented the absence of anti-CCP antibody produc-
tion among healthy individuals [9,10,31]. Our study reported
that carrier of HLA–DRB1 01, 04 and 10 was associated with
production of anti-CCP antibodies being significant only with
04. Previous studies found that carrier of one or two HLA–
DRB1 SE alleles was significantly associated with production
of anti-CCP antibodies in a Dutch RA population [14,25].
Our study revealed that in the Egyptian patients, the presence
of one or more of the alleles studied, was significantly associ-ated with anti-CCP positive RA. Berglin et al. [33], Hughes
et al. [34] and Kaltenhauser et al. [25] found that the HLA-
DRB1 01 and 04 SE alleles conferred the highest risk for devel-
opment of anti-CCP antibodies in RA patients.
There was a significant correlation between high serum level
of anti-CCP antibodies and HLA-DRB1 (04 and 10) alleles,
SDAI score, radiological and clinical severity score. This
agrees with Gourrand et al. [7] and Berglin et al. [33] who sug-
gested that measurement of serum anti-CCP levels might be of
clinical significance for detection of disease severity and activ-
ity. They mentioned that RA patients with positive SE and
positive anti-CCP had a significantly higher rate of destruction
in the joints than did all other patients. Which means that a
higher rate of joint damage was only found when both SE alle-
les and anti-CCP antibodies were present. A previous study
reported that the SE alleles correlated with the presence of
anti-CCP Abs, but not with the presence of RF [35]. Also
Kinikli and associates [32] reported no association with sero-
positivity of RA. This coincides with our results. On other
hand Ucar et al., found that HLA-DRB1*01 and *04 were
determined to be higher in RA patients with +RF [36].
HLA-DRB1 04 was associated with RA in 60% of the
patients in our study; therefore, the possibility that other genes
may add to the pathogenesis of RA cannot be denied. In addi-
tion to genetic factors, some environmental factors have been
concerned as predictors of RA. The 2–3-fold higher prevalence
of the disease in women, primarily before menopause, has been
interpreted as indicating a role for hormonal or reproductive
factors [32]. Smoking is a well-established risk factor for the
development of RA and it was found that smoking contributes
to the development of RA in SE positive and anti-CCP posi-
tive patients [15], indicating that the predisposition to RA
may be due to an interaction between genetic and environmen-
tal factors.
In conclusion, HLA-DRB1 04 was associated with RA
Egyptian patients particularly those positive to anti-CCP anti-
bodies. It was strongly associated in the production of elevated
titers of anti-CCP antibodies which contribute to the disease
development, severity and activity of RA disease. The presence
of anti-CCP antibodies and/or HLADRB1 04 or 10 is associ-
ated with a poor radiological outcome whereas 01 and 04 are
associated with higher grade of disease activity and clinical
severity. Therefore the identification of susceptible allele in
RA patients may assist a physician to take early decision
274 A.F. Soliman et al.regarding starting of intensive therapy to prevent joint dam-
age. Further longitudinal studies are recommended with large
numbers of patients and controls to assess the predictive role
of each allele in RA susceptibility, to study the polymorphic
character of HLA genes and to emphasize the relationships
of environmental with genetic factors.
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